Table 5.
Characteristics of the Patient-Reported Outcome Measures (PROMs) From the Secondary Analysis
| Domain | PROM | Applied in population with encephalitis | Total number of patients | Applied in population with encephalopathy | Total number of patients |
| HRQoL | SF-36 | All-cause encephalitis23 | 61 | Hepatic encephalopathy17,19-22,24-28 Lyme encephalopathy18 |
1,219 37 |
| SIP | — | — | Hepatic encephalopathy29-37 | 787 | |
| Euro-QOL-5D | Viral encephalitis38 | 1,107 | Hepatic encephalopathy39 | 38 | |
| QOLIBRI-OS | Anti-NMDAR encephalitis40 | 3 | — | — | |
| NHP | — | — | Hepatic encephalopathy27 | 554 | |
| LQoLP | All-cause encephalitis3 | 72 | — | — | |
| BIPQ | All-cause encephalitis3,41 | 517 | — | — | |
| PROMIS HRQoL | — | — | Hepatic encephalopathy42 | 83 | |
| PROMIS Impact of Illness | Anti-NMDAR encephalitis43 | 61 | — | — | |
| PedsQL | Anti-NMDAR encephalitis,7 ADEM,44 all-cause encephalitis45,46 |
141 | — | — | |
| Neuro-QOL | Cryptococcal meningoencephalitis47 | 46 | — | — | |
| CLDQ | — | — | Hepatic encephalopathy26,28,48-50 | 521 | |
| Functioning and community integration | ESGQ | Tick-borne encephalitis12 | 96 | — | — |
| EBIQ | All-cause encephalitis51 | 266 | — | — | |
| BIRCO39 | Anti-NMDAR encephalitis40 | 3 | — | — | |
| ESS1 | All-cause encephalitis3 | 72 | — | — | |
| Emotional well-being and mood | BDI II | All-cause encephalitis,3,54 cryptococcal meningoencephalitis,47 autoimmune encephalitis,52 anti-NMDAR encephalitis53 | 716 | — | — |
| HADS | Anti-NMDAR encephalitis5,40 | 10 | Hepatic encephalopathy24 | 15 | |
| SDS | Anti-NMDAR encephalitis55 | 16 | — | — | |
| WHO-5 Well-Being index | Herpes simplex encephalitis56 | 26 | Hepatic encephalopathy24 | 15 | |
| M3VAS | All-cause encephalitis41 | 445 | — | — | |
| PDSQ | All-cause encephalitis41 | 445 | — | — | |
| BAI | Cryptococcal meningoencephalitis,47 anti-NMDAR encephalitis53 | 49 | — | — | |
| SAS | Anti-NMDAR encephalitis55 | 16 | Lyme encephalopathy18 | 37 | |
| Sleep and fatigue | MFIS | Autoimmune encephalitis52 | 407 | — | — |
| PSQI | Autoimmune encephalitis,52 anti-LGI1 encephalitis58 | 452 | Hepatic encephalopathy21,24 | 65 | |
| ESS2 | All-cause encephalitis54, autoimmune limbic encephalitis59 | 200 | Hepatic encephalopathy21,24 | 65 | |
| ISI | All-cause encephalitis54 | 188 | — | — | |
| FOSQ | Tick-borne encephalitis12 | 96 | — | — | |
| FSS | All-cause encephalitis54 | 188 | Lyme encephalopathy18 | 37 |
Abbreviation: ADEM = acute disseminated encephalomyelitis; BDI = Beck Depression Inventory; BIPQ = Brief Illness Perception Questionnaire; CLDQ = Chronic Liver Disease Questionnaire; EBIQ = European Brain Injury Questionnaire; ESGQ = Encephalitis Support Group Questionnaire 2000; ESS = Epworth Sleepiness Score; FOSQ = Functional Outcome of Sleep Questionnaire; FSS = Fatigue Severity Scale; HADS = Hospital Anxiety and Depression Scale; ISI = Insomnia Severity Index; LQoLP = Lancashire Quality of Life Profile; M3VAS = Maudsley three-item VAS; MFIS = Modified Fatigue Impact Scale; NHP = Nottingham Health Profile; PDSQ = Psychiatric Diagnostic Screening Questionnaire; PedsQL = Pediatric Quality of Life Inventory; QOLIBRI-OS = Quality of Life after Brain Injury–Overall Scale; SDS = Self-Rating Depression Scale; SIP = Sickness Impact Profile.
1 = Environmental Status Scale; 2 = Epworth Sleepiness Score.